Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Lung Adenocarcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non Small Cell Lung Cancer (3075
)
Lung Non-Squamous Non-Small Cell Cancer (123
)
Lung Non-Small Cell Squamous Cancer (97
)
Non Small Cell Lung Cancer (3075
)
Lung Non-Squamous Non-Small Cell Cancer (123
)
Lung Non-Small Cell Squamous Cancer (97
)
›
Associations
(558)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
MET F1200I
Lung Adenocarcinoma
MET F1200I
Lung Adenocarcinoma
TPX-0022
Sensitive: C4 – Case Studies
IASLC-TTLC 2023 - 5 days (New C4)
TPX-0022
Sensitive
:
C4
IASLC-TTLC 2023 - 5d
TPX-0022
Sensitive: C4 – Case Studies
IASLC-TTLC 2023 - 5 days
TPX-0022
Sensitive
:
C4
IASLC-TTLC 2023 - 5 days - (New C4)
MET H1094Y
Lung Adenocarcinoma
MET H1094Y
Lung Adenocarcinoma
TPX-0022
Sensitive: C4 – Case Studies
IASLC-TTLC 2023 - 5 days (New C4)
TPX-0022
Sensitive
:
C4
IASLC-TTLC 2023 - 5d
TPX-0022
Sensitive: C4 – Case Studies
IASLC-TTLC 2023 - 5 days
TPX-0022
Sensitive
:
C4
IASLC-TTLC 2023 - 5 days - (New C4)
EML4-ALK fusion
Lung Adenocarcinoma
EML4-ALK fusion
Lung Adenocarcinoma
alectinib
Sensitive: C4 – Case Studies
Anticancer Drugs - 1 week (New C4)
alectinib
Sensitive
:
C4
Anticancer Drugs - 1wk
alectinib
Sensitive: C4 – Case Studies
Anticancer Drugs - 1 week
alectinib
Sensitive
:
C4
Anticancer Drugs - 1 week - (New C4)
EGFR exon 19 deletion + EGFR C797S
Lung Adenocarcinoma
EGFR exon 19 deletion + EGFR C797S
Lung Adenocarcinoma
osimertinib + anlotinib
Sensitive: C4 – Case Studies
Pharmacol Res - 2 weeks (New C4)
osimertinib + anlotinib
Sensitive
:
C4
Pharmacol Res - 2wk
osimertinib + anlotinib
Sensitive: C4 – Case Studies
Pharmacol Res - 2 weeks
osimertinib + anlotinib
Sensitive
:
C4
Pharmacol Res - 2 weeks - (New C4)
EGFR L860R
Lung Adenocarcinoma
EGFR L860R
Lung Adenocarcinoma
osimertinib
Sensitive: D – Preclinical
Cancer Lett - 2 weeks (New D)
osimertinib
Sensitive
:
D
Cancer Lett - 2wk
osimertinib
Sensitive: D – Preclinical
Cancer Lett - 2 weeks
osimertinib
Sensitive
:
D
Cancer Lett - 2 weeks - (New D)
SERPINH1 overexpression
Lung Adenocarcinoma
SERPINH1 overexpression
Lung Adenocarcinoma
vinorelbine tartrate
Sensitive: D – Preclinical
J Thorac Dis - 4 weeks (New D)
vinorelbine tartrate
Sensitive
:
D
J Thorac Dis - 4wk
vinorelbine tartrate
Sensitive: D – Preclinical
J Thorac Dis - 4 weeks
vinorelbine tartrate
Sensitive
:
D
J Thorac Dis - 4 weeks - (New D)
SERPINH1 overexpression
Lung Adenocarcinoma
SERPINH1 overexpression
Lung Adenocarcinoma
midostaurin
Sensitive: D – Preclinical
J Thorac Dis - 4 weeks (New D)
midostaurin
Sensitive
:
D
J Thorac Dis - 4wk
midostaurin
Sensitive: D – Preclinical
J Thorac Dis - 4 weeks
midostaurin
Sensitive
:
D
J Thorac Dis - 4 weeks - (New D)
SERPINH1 overexpression
Lung Adenocarcinoma
SERPINH1 overexpression
Lung Adenocarcinoma
doxorubicin hydrochloride
Sensitive: D – Preclinical
J Thorac Dis - 4 weeks (New D)
doxorubicin hydrochloride
Sensitive
:
D
J Thorac Dis - 4wk
doxorubicin hydrochloride
Sensitive: D – Preclinical
J Thorac Dis - 4 weeks
doxorubicin hydrochloride
Sensitive
:
D
J Thorac Dis - 4 weeks - (New D)
SERPINH1 overexpression
Lung Adenocarcinoma
SERPINH1 overexpression
Lung Adenocarcinoma
sunitinib
Sensitive: D – Preclinical
J Thorac Dis - 4 weeks (New D)
sunitinib
Sensitive
:
D
J Thorac Dis - 4wk
sunitinib
Sensitive: D – Preclinical
J Thorac Dis - 4 weeks
sunitinib
Sensitive
:
D
J Thorac Dis - 4 weeks - (New D)
SERPINH1 overexpression
Lung Adenocarcinoma
SERPINH1 overexpression
Lung Adenocarcinoma
paclitaxel
Sensitive: D – Preclinical
J Thorac Dis - 4 weeks (New D)
paclitaxel
Sensitive
:
D
J Thorac Dis - 4wk
paclitaxel
Sensitive: D – Preclinical
J Thorac Dis - 4 weeks
paclitaxel
Sensitive
:
D
J Thorac Dis - 4 weeks - (New D)
SERPINH1 overexpression
Lung Adenocarcinoma
SERPINH1 overexpression
Lung Adenocarcinoma
lapatinib
Sensitive: D – Preclinical
J Thorac Dis - 4 weeks (New D)
lapatinib
Sensitive
:
D
J Thorac Dis - 4wk
lapatinib
Sensitive: D – Preclinical
J Thorac Dis - 4 weeks
lapatinib
Sensitive
:
D
J Thorac Dis - 4 weeks - (New D)
SERPINH1 overexpression
Lung Adenocarcinoma
SERPINH1 overexpression
Lung Adenocarcinoma
etoposide oral
Sensitive: D – Preclinical
J Thorac Dis - 4 weeks (New D)
etoposide oral
Sensitive
:
D
J Thorac Dis - 4wk
etoposide oral
Sensitive: D – Preclinical
J Thorac Dis - 4 weeks
etoposide oral
Sensitive
:
D
J Thorac Dis - 4 weeks - (New D)
SERPINH1 overexpression
Lung Adenocarcinoma
SERPINH1 overexpression
Lung Adenocarcinoma
cyclopamine
Sensitive: D – Preclinical
J Thorac Dis - 4 weeks (New D)
cyclopamine
Sensitive
:
D
J Thorac Dis - 4wk
cyclopamine
Sensitive: D – Preclinical
J Thorac Dis - 4 weeks
cyclopamine
Sensitive
:
D
J Thorac Dis - 4 weeks - (New D)
No biomarker
Lung Adenocarcinoma
No biomarker
Lung Adenocarcinoma
nintedanib
Sensitive: A1 - Approval
nintedanib
Sensitive
:
A1
nintedanib
Sensitive: A1 - Approval
nintedanib
Sensitive
:
A1
PD-L1 underexpression
Lung Adenocarcinoma
PD-L1 underexpression
Lung Adenocarcinoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
No biomarker
Lung Adenocarcinoma
No biomarker
Lung Adenocarcinoma
DP
Sensitive: A2 - Guideline
DP
Sensitive
:
A2
DP
Sensitive: A2 - Guideline
DP
Sensitive
:
A2
No biomarker
Lung Adenocarcinoma
No biomarker
Lung Adenocarcinoma
GC
Sensitive: A2 - Guideline
GC
Sensitive
:
A2
GC
Sensitive: A2 - Guideline
GC
Sensitive
:
A2
No biomarker
Lung Adenocarcinoma
No biomarker
Lung Adenocarcinoma
cisplatin + pemetrexed
Sensitive: A2 - Guideline
cisplatin + pemetrexed
Sensitive
:
A2
cisplatin + pemetrexed
Sensitive: A2 - Guideline
cisplatin + pemetrexed
Sensitive
:
A2
No biomarker
Lung Adenocarcinoma
No biomarker
Lung Adenocarcinoma
albumin-bound paclitaxel
Sensitive: A2 - Guideline
albumin-bound paclitaxel
Sensitive
:
A2
albumin-bound paclitaxel
Sensitive: A2 - Guideline
albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Lung Adenocarcinoma
No biomarker
Lung Adenocarcinoma
durvalumab + tremelimumab
Sensitive: A2 - Guideline
durvalumab + tremelimumab
Sensitive
:
A2
durvalumab + tremelimumab
Sensitive: A2 - Guideline
durvalumab + tremelimumab
Sensitive
:
A2
No biomarker
Lung Adenocarcinoma
No biomarker
Lung Adenocarcinoma
cemiplimab
Sensitive: A2 - Guideline
cemiplimab
Sensitive
:
A2
cemiplimab
Sensitive: A2 - Guideline
cemiplimab
Sensitive
:
A2
EGFR mutation
Lung Adenocarcinoma
EGFR mutation
Lung Adenocarcinoma
gefitinib
Sensitive: B - Late Trials
gefitinib
Sensitive
:
B
gefitinib
Sensitive: B - Late Trials
gefitinib
Sensitive
:
B
EGFR T790M
Lung Adenocarcinoma
EGFR T790M
Lung Adenocarcinoma
erlotinib
Sensitive: B - Late Trials
erlotinib
Sensitive
:
B
erlotinib
Sensitive: B - Late Trials
erlotinib
Sensitive
:
B
EGFR exon 19 deletion
Lung Adenocarcinoma
EGFR exon 19 deletion
Lung Adenocarcinoma
gefitinib
Sensitive: B - Late Trials
gefitinib
Sensitive
:
B
gefitinib
Sensitive: B - Late Trials
gefitinib
Sensitive
:
B
EGFR mutation
Lung Adenocarcinoma
EGFR mutation
Lung Adenocarcinoma
afatinib
Sensitive: B - Late Trials
afatinib
Sensitive
:
B
afatinib
Sensitive: B - Late Trials
afatinib
Sensitive
:
B
EGFR exon 19 deletion
Lung Adenocarcinoma
EGFR exon 19 deletion
Lung Adenocarcinoma
afatinib
Sensitive: B - Late Trials
afatinib
Sensitive
:
B
afatinib
Sensitive: B - Late Trials
afatinib
Sensitive
:
B
EGFR L858R
Lung Adenocarcinoma
EGFR L858R
Lung Adenocarcinoma
gefitinib
Sensitive: B - Late Trials
gefitinib
Sensitive
:
B
gefitinib
Sensitive: B - Late Trials
gefitinib
Sensitive
:
B
EGFR L858R
Lung Adenocarcinoma
EGFR L858R
Lung Adenocarcinoma
erlotinib
Resistant: B - Late Trials
erlotinib
Resistant
:
B
erlotinib
Resistant: B - Late Trials
erlotinib
Resistant
:
B
EGFR T790M
Lung Adenocarcinoma
EGFR T790M
Lung Adenocarcinoma
gefitinib
Sensitive: B - Late Trials
gefitinib
Sensitive
:
B
gefitinib
Sensitive: B - Late Trials
gefitinib
Sensitive
:
B
HER-2 exon 20 insertion + TMB-L + PD-L1 negative
Lung Adenocarcinoma
HER-2 exon 20 insertion + TMB-L + PD-L1 negative
Lung Adenocarcinoma
Immunotherapy
Sensitive: B - Late Trials
Immunotherapy
Sensitive
:
B
Immunotherapy
Sensitive: B - Late Trials
Immunotherapy
Sensitive
:
B
EGFR L858R
Lung Adenocarcinoma
EGFR L858R
Lung Adenocarcinoma
afatinib
Sensitive: B - Late Trials
afatinib
Sensitive
:
B
afatinib
Sensitive: B - Late Trials
afatinib
Sensitive
:
B
EGFR mutation
Lung Adenocarcinoma
EGFR mutation
Lung Adenocarcinoma
bevacizumab + erlotinib
Sensitive: C1 - Off-label
bevacizumab + erlotinib
Sensitive
:
C1
bevacizumab + erlotinib
Sensitive: C1 - Off-label
bevacizumab + erlotinib
Sensitive
:
C1
PD-L1 expression
Lung Adenocarcinoma
PD-L1 expression
Lung Adenocarcinoma
atezolizumab
Sensitive: C1 - Off-label
atezolizumab
Sensitive
:
C1
atezolizumab
Sensitive: C1 - Off-label
atezolizumab
Sensitive
:
C1
MET exon 14 mutation
Lung Adenocarcinoma
MET exon 14 mutation
Lung Adenocarcinoma
tepotinib
Sensitive: C1 - Off-label
tepotinib
Sensitive
:
C1
tepotinib
Sensitive: C1 - Off-label
tepotinib
Sensitive
:
C1
EGFR exon 19 deletion
Lung Adenocarcinoma
EGFR exon 19 deletion
Lung Adenocarcinoma
osimertinib
Sensitive: C1 - Off-label
osimertinib
Sensitive
:
C1
osimertinib
Sensitive: C1 - Off-label
osimertinib
Sensitive
:
C1
BRAF V600E
Lung Adenocarcinoma
BRAF V600E
Lung Adenocarcinoma
trametinib + dabrafenib
Sensitive: C1 - Off-label
trametinib + dabrafenib
Sensitive
:
C1
trametinib + dabrafenib
Sensitive: C1 - Off-label
trametinib + dabrafenib
Sensitive
:
C1
ATM mutation
Lung Adenocarcinoma
ATM mutation
Lung Adenocarcinoma
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
EGFR T790M
Lung Adenocarcinoma
EGFR T790M
Lung Adenocarcinoma
osimertinib
Resistant: C1 - Off-label
osimertinib
Resistant
:
C1
osimertinib
Resistant: C1 - Off-label
osimertinib
Resistant
:
C1
EGFR L858R
Lung Adenocarcinoma
EGFR L858R
Lung Adenocarcinoma
osimertinib
Sensitive: C1 - Off-label
osimertinib
Sensitive
:
C1
osimertinib
Sensitive: C1 - Off-label
osimertinib
Sensitive
:
C1
EGFR mutation
Lung Adenocarcinoma
EGFR mutation
Lung Adenocarcinoma
erlotinib
Sensitive: C1 - Off-label
erlotinib
Sensitive
:
C1
erlotinib
Sensitive: C1 - Off-label
erlotinib
Sensitive
:
C1
EGFR mutation
Lung Adenocarcinoma
EGFR mutation
Lung Adenocarcinoma
osimertinib
Sensitive: C1 - Off-label
osimertinib
Sensitive
:
C1
osimertinib
Sensitive: C1 - Off-label
osimertinib
Sensitive
:
C1
RET fusion
Lung Adenocarcinoma
RET fusion
Lung Adenocarcinoma
pralsetinib
Sensitive: C1 - Off-label
pralsetinib
Sensitive
:
C1
pralsetinib
Sensitive: C1 - Off-label
pralsetinib
Sensitive
:
C1
ALK positive
Lung Adenocarcinoma
ALK positive
Lung Adenocarcinoma
lorlatinib
Sensitive: C1 - Off-label
lorlatinib
Sensitive
:
C1
lorlatinib
Sensitive: C1 - Off-label
lorlatinib
Sensitive
:
C1
MET exon 14 mutation
Lung Adenocarcinoma
MET exon 14 mutation
Lung Adenocarcinoma
capmatinib
Sensitive: C1 - Off-label
capmatinib
Sensitive
:
C1
capmatinib
Sensitive: C1 - Off-label
capmatinib
Sensitive
:
C1
MET exon 14 mutation
Lung Adenocarcinoma
MET exon 14 mutation
Lung Adenocarcinoma
savolitinib
Sensitive: C1 - Off-label
savolitinib
Sensitive
:
C1
savolitinib
Sensitive: C1 - Off-label
savolitinib
Sensitive
:
C1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login